MétaCan
Menu
Back to cohort
Record W4403947139 · doi:10.1038/s41408-024-01165-w

Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation

2024· article· en· W4403947139 on OpenAlexaff
Oren Pasvolsky, Curtis Marcoux, Denái R. Milton, Babar Pal, Mark R. Tanner, Qaiser Bashir, Samer A. Srour, Jae‐Hyun Lee, Neeraj Saini, Paul Lin, Jeremy Ramdial, Yago Nieto, Guilin Tang, Yosra Aljawai, Partow Kebriaei, Melody Becnel, Hans C. Lee, Krina K. Patel, Sheeba K. Thomas, Robert Z. Orlowski, Elizabeth J. Shpall, R. Champlin, Muzaffar H. Qazilbash

Bibliographic record

VenueBlood Cancer Journal · 2024
Typearticle
Languageen
FieldMedicine
TopicMultiple Myeloma Research and Treatments
Canadian institutionsDalhousie University
FundersNational Cancer InstituteUniversity of Texas MD Anderson Cancer CenterDr. Miriam and Sheldon G. Adelson Medical Research FoundationLeukemia and Lymphoma SocietyU.S. Department of Health and Human Services
KeywordsCD34MedicinePlerixaforMultiple myelomaHematopoietic stem cell transplantationTransplantationAutologous stem-cell transplantationMelphalanHaematopoiesisPropensity score matchingInternal medicineUrologyStem cellSurgeryOncologyCXCR4Biology

Abstract

fetched live from OpenAlex

Abstract Autologous transplantation remains the standard of care for eligible multiple myeloma (MM) patients, yet optimal CD34 + cell dose remains unclear. We conducted a retrospective study on MM patients undergoing upfront transplant between 2005 and 2021 and divided them into low (≤2.5 × 10 6 cells/kg) and high (>2.5 × 10 6 cells/kg) CD34 + dose groups. We included 2479 patients, 95 in the low CD34 + group and 2384 in the high CD34 + group. Patients in the low CD34 + group were older (63.2 vs 61.1 years, p = 0.013), more often had R-ISS III (19% vs 9%, p = 0.014), received plerixafor (60% vs 35%, p < 0.001) and transplanted after 2009 (88% vs 80%, p = 0.047). Time to neutrophil and platelet recovery was longer in the low CD34 + group. Median PFS and OS were lower in the low CD34 + group (31.6 vs. 43.6 months, p = 0.011 and 76.4 vs. 108.2 months, p < 0.001, respectively). Evaluation of incrementally higher CD34 + dose did not show significant improvement in survival at thresholds >2.5 × 10 6 cells/kg. Multivariable analysis affirmed that CD34 + >2.5 × 10 6 cells/kg was associated with better PFS (HR 0.71, p = 0.008) and OS (0.59, p < 0.001). After propensity score matching, a CD34 + dose >2.5 × 10 6 cells/kg remained a predictor of better OS (0.42, p < 0.001). In conclusion, CD34 + dose >2.5 × 10 6 cells/kg was associated with improved survival, without any additional benefit at incrementally higher doses.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.083
Threshold uncertainty score0.861

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.019
GPT teacher head0.278
Teacher spread0.259 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations9
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueBlood Cancer JournalSame topicMultiple Myeloma Research and TreatmentsFrench-language works237,207